Introducing the next generation of cannabis vapourizer technology


Introducing the next generation of cannabis vapourizer technology

A new generation of vapourizer devices is changing how people with chronic conditions use their medical cannabis while potentially lowering the risks associated with some forms of inhalation.

Inhaled medical cannabis has rapid onset of effects

The Canadian Pain Society(1) and the European Federation of Neurological Societies(2) recommend medical cannabis as a second- or third-line treatment option for chronic neuropathic pain.

Inhaling medical cannabis leads to the onset of effects within seconds to minutes. This is why inhalation is a viable alternative for patients whose symptoms require rapid onset of action and whose symptoms are not managed fast enough with orally ingested formats such as softgels or oil.

There are two issues for those who want the rapid onset of potential pain relief offered by inhalation: they want to avoid using illicit vape devices and they wish to reduce the risks of traditional smoking.

Our cannabis vapourizers are a reliable alternative

Under the first wave of legalization in Canada, only vapourizers that used milled cannabis flowers were allowed. These vapourizers have the benefit of heating cannabis—which is the only ingredient—at a lower temperature than smoked cannabis, hence releasing the active compounds as vapour rather than smoke. This may minimize human exposure to the by-products of combustion.

Now, Spectrum Therapeutics is pleased to offer the next generation of vapourizer technology, which contains cannabis extract and terpenes in an easy-to-use, portable design. The vape is composed of two parts: a cartridge filled with cannabis extract and a separate battery unit designed to fit 510 threaded cartridges.

Few ingredients, simple hardware design

Canopy Growth has developed a new generation of vape hardware and formulations from the ground up. Recent reports on the safety of vapes underscore the importance of federal regulation of cannabis products, including vape pens. Our vapes are tamper-proof, traceable, and adhere to all Health Canada regulations. 

Trusting the ingredients of any vape pen is important, which is why we keep our cannabis cartridge ingredient list to a minimum:

  • The cartridges contain cannabis extract and added terpenes
  • Each extract contains THC, CBD, or a combination of the two depending on the cartridge purchased
  • No added vitamins, minerals, nicotine, alcohol, caffeine, sugars, sweeteners, or colours
  • We are committed to a high standard for cannabis extracts derived without the use of carrier oils and diluents such as vitamin E acetate

Designed from the ground up

  • Made using only premium, inert materials—surgical-grade steel and borosilicate glass—for any part that comes into contact with the cannabis extract.
  • All our vapourizer products are produced using the UL 8139 Certified™ safe manufacturing standard, meaning that each electronics component of our hardware—including the battery—has been reviewed and certified by UL.*
  • 3 cannabis cartridge products are available at in our easy-to-use Spectrum Framework.

With engineered design and innovative cannabis extract formulations, our vape pens offer an alternative to smoking and the use of illicit vape devices.

Disclaimer (from executive notes)

There may be health risks associated with vaping that are not fully known or understood. Refer to the following for risks of vaping:

*UL stands for Underwriters Laboratories, an organization in business for more than 100 years. UL is a world leader in product safety testing and certification. UL developed industry standard UL 8139 to help manufacturers address lithium battery hazards for vaping devices. UL 8139 evaluates the safety of the electrical, heating, battery, and charging systems of these products.


  1. Moulin DE, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag 2014;19(6):328-335.
  2. Attal N, Cruccu G, Baron R, et al. 2010. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17(9):1113-e88.

This communication is intended for adults only in the province in which it is distributed and should not be shared with minors.